Roche has revealed the data behind a positive phase 3 trial for its oral BTK inhibitor fenebrutinib in primary progressive multiple sclerosis (PPMS), revealing that it was at least as effective as its ...
Shares in Sanofi were sliding today after a double dose of bad news for its oral BTK inhibitor tolebrutinib, in development as a therapy for multiple sclerosis (MS). Along with what looks set to be ...
Cloudflare, Inc. engages in the provision of cloud-based services to secure websites. It offers various products for performance and reliability, video streaming and delivery, advanced security, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results